NSRX — Nasus Pharma Income Statement
0.000.00%
Last trade - 00:00Annual income statement for Nasus Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2022 March 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 20-F |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Total Operating Expenses | 4.08 | 2.29 | 2.16 | 9.81 |
| Operating Profit | -4.08 | -2.29 | -2.16 | -9.81 |
| Total Net Non Operating Interest Income / Expense | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -4.3 | -2.01 | -3.1 | -11.6 |
| Net Income After Taxes | -4.3 | -2.01 | -3.1 | -11.6 |
| Net Income Before Extraordinary Items | ||||
| Extraordinary Items | ||||
| Net Income | -3.42 | -2.1 | -3.06 | -11.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -3.42 | -2.1 | -3.06 | -11.7 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.475 | -0.222 | -0.343 | -1.45 |